AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31119289 — intervention group
Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 0.50
Number of subjects: 430
Study 31119289 — intervention group
Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 0.62
Number of subjects: 430
Study 31119289 — intervention group
Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 0.75
Number of subjects: 430
Study 31119289 — intervention group
Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 0.88
Number of subjects: 430
Study 31119289 — intervention group
Group type: EXPERIMENTAL
Intervention: SID Val:Lys ratio of 1.00
Number of subjects: 430
Study 28890331 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative opioid counseling
Number of subjects: 0
Study 28890331 — intervention group
Group type: COMPARATOR
Intervention: No counseling (Control)
Number of subjects: 0
Study 26721012 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - Lingual flap retraction in addition to buccal flap
Number of subjects: 380
Study 26721012 — intervention group
Group type: COMPARATOR
Intervention: Group B - Retraction of buccal flap only
Number of subjects: 380
Study 23866554 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal spectral filter
Number of subjects: 0
Study 23866554 — intervention group
Group type: COMPARATOR
Intervention: Grey filter
Number of subjects: 0
Study 23866554 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal spectral filter (after crossover)
Number of subjects: 0
Study 23866554 — intervention group
Group type: COMPARATOR
Intervention: Grey filter (after crossover)
Number of subjects: 0
Study 21389303 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoviscous, isosweet fat emulsions of increasing fat concentration
Number of subjects: 0
Study 21389303 — intervention group
Group type: EXPERIMENTAL
Intervention: Taster status (TS)
Number of subjects: 0
Study 21389303 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmenting populations by taster status (TS)
Number of subjects: 0
Study 19028055 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE/nitinol self-expanding stent graft
Number of subjects: 100
Study 19028055 — intervention group
Group type: COMPARATOR
Intervention: Surgical femoral to above knee popliteal artery bypass with synthetic graft material
Number of subjects: 100
Study 17909718 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (30 mg/kg BW methylprednisolone intravenously)
Number of subjects: 20
Study 17909718 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo infusion)
Number of subjects: 20
Study 14973302 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg (single dose)
Number of subjects: 76
Study 14973302 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 400 mg, 600 mg, or 800 mg (repeat dose for 5 days)
Number of subjects: 76
Study 14973302 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin (any dosage)
Number of subjects: 76
Study 11280420 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Eyes Test
Number of subjects: 15
Study 11280420 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 15
Study 9395428 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus CMF (8 cycles)
Number of subjects: 1708
Study 9395428 — intervention group
Group type: COMPARATOR
Intervention: CMF alone (9 cycles)
Number of subjects: 1708
Study 8343782 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel ultrasound
Number of subjects: 20
Study 8343782 — intervention group
Group type: COMPARATOR
Intervention: Tap water immersion ultrasound
Number of subjects: 20
Study 3554085 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (MeCCNU + 5‐FU) + Levamisole
Number of subjects: 29
Study 3554085 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy (MeCCNU + 5‐FU)
Number of subjects: 29
Study 30196779 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye muscle exercises
Number of subjects: 0
Study 30196779 — intervention group
Group type: COMPARATOR
Intervention: Prism management
Number of subjects: 0
Study 26094549 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate gel (two‐compound gel) applied once daily
Number of subjects: 0
Study 26094549 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol scalp solution applied twice daily
Number of subjects: 0
Study 26094549 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate gel (two‐compound gel)
Number of subjects: 0
Study 24951495 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy
Number of subjects: 315
Study 24951495 — intervention group
Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 315
Study 24951495 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 315
Study 24951495 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level and past quit attempt
Number of subjects: 315
Study 22293362 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care model for depression
Number of subjects: 0
Study 22293362 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care model
Number of subjects: 0
Study 22293362 — intervention group
Group type: EXPERIMENTAL
Intervention: NPT constructs 'coherence' and 'cognitive participation'
Number of subjects: 0
Study 20035494 — intervention group
Group type: EXPERIMENTAL
Intervention: creatine + carbohydrate
Number of subjects: 7
Study 20035494 — intervention group
Group type: EXPERIMENTAL
Intervention: creatine + protein, amino acids, and carbohydrate
Number of subjects: 7
Study 20035494 — intervention group
Group type: COMPARATOR
Intervention: creatine alone
Number of subjects: 7
Study 18364135 — intervention group
Group type: EXPERIMENTAL
Intervention: CartoMerge
Number of subjects: 81
Study 18364135 — intervention group
Group type: COMPARATOR
Intervention: CartoXP
Number of subjects: 81
Study 15751090 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 153
Study 15751090 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 153
Study 15751090 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg
Number of subjects: 153
Study 15751090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 15751090 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine prophylaxis
Number of subjects: 153
Study 12006133 — intervention group
Group type: EXPERIMENTAL
Intervention: Balmandol
Number of subjects: 0
Study 12006133 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 12006133 — intervention group
Group type: COMPARATOR
Intervention: Eucerin
Number of subjects: 0
Study 10593379 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 67
Study 10593379 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 67
Study 8736649 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 0
Study 8736649 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 0
Study 1612362 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 2000 mg daily for 30 days
Number of subjects: 26
Study 1612362 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 2000 mg daily for 4 weeks
Number of subjects: 26
Study 1612362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6322674 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontract therapeutic touch
Number of subjects: 0
Study 6322674 — intervention group
Group type: COMPARATOR
Intervention: Mimic control intervention
Number of subjects: 0
Study 30634889 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 200
Study 30634889 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 200
Study 28289280 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐methylfolate 15 mg
Number of subjects: 55
Study 28289280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 26872005 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (12 weeks)
Number of subjects: 52
Study 24258313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT) with cyproterone acetate (CPA) 100 mg tid
Number of subjects: 366
Study 24258313 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment (CT) with cyproterone acetate (CPA) 100 mg tid
Number of subjects: 366
Study 24258313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT)
Number of subjects: 366
Study 24258313 — intervention group
Group type: COMPARATOR
Intervention: Intermittent treatment (IT) and Continuous treatment (CT)
Number of subjects: 366
Study 22437221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) with SSRIs/SNRIs
Number of subjects: 575
Study 22437221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) without SSRIs/SNRIs
Number of subjects: 575
Study 22437221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER with SSRIs/SNRIs during double-blind treatment phase
Number of subjects: 575
Study 22437221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER without SSRIs/SNRIs during double-blind treatment phase
Number of subjects: 575
Study 22437221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER with SSRIs/SNRIs
Number of subjects: 575
Study 22437221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER without SSRIs/SNRIs
Number of subjects: 575
Study 19948944 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 107
Study 19948944 — intervention group
Group type: COMPARATOR
Intervention: Control (no gum)
Number of subjects: 107
Study 18202091 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 300 mg/kg over 24 h
Number of subjects: 110
Study 18202091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 16002451 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) administration (7.5 IU or 2.5 mg)
Number of subjects: 7
Study 16002451 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 7
Study 14641610 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 10 mg/kg bodyweight
Number of subjects: 36
Study 14641610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10377504 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment for up to 42 months
Number of subjects: 71
Study 8667301 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated prosodic contour of sentences
Number of subjects: 0
Study 8667301 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration and F0 contour of main-clause verb
Number of subjects: 0
Study 8667301 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated duration of main-clause verb
Number of subjects: 0
Study 1994787 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemirolast 50 mg bid
Number of subjects: 31
Study 1994787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6583195 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 0
Study 6583195 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 0
Study 6583195 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 0
Study 31321800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,540 nm fractional erbium-glass laser therapy plus topical minoxidil solution applied twice daily for 6 weeks
Number of subjects: 0
Study 31321800 — intervention group
Group type: COMPARATOR
Intervention: Topical minoxidil solution only
Number of subjects: 0
Study 30646142 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term nicotine replacement therapy (LT-NRT) for 12 months with 6 follow-up counseling sessions
Number of subjects: 398
Study 30646142 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation (SSC) treatment for 10 weeks with 4 follow-up counseling sessions
Number of subjects: 398
Study 30646142 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers in SSC
Number of subjects: 398
Study 30646142 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing smokers in LT-NRT
Number of subjects: 398
Study 27643726 — intervention group
Group type: EXPERIMENTAL
Intervention: Alive-PD intervention
Number of subjects: 339
Study 24715706 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-536 (0.0625-0.25 mg/kg)
Number of subjects: 32
Study 24715706 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-536 (0.25 mg/kg)
Number of subjects: 32
Study 24715706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23089084 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples treatment approach
Number of subjects: 89
Study 23089084 — intervention group
Group type: COMPARATOR
Intervention: Control group (waited about 3 months for treatment)
Number of subjects: 89
Study 19443133 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone (IM) maintenance
Number of subjects: 319
Study 19443133 — intervention group
Group type: COMPARATOR
Intervention: Waiting list for methadone treatment
Number of subjects: 319
Study 19443133 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants not in methadone treatment at 4 and 10 months
Number of subjects: 319
Study 17804330 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐percha and Pulp Canal Sealer
Number of subjects: 50
Study 17804330 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon, Epiphany primer, and Epiphany
Number of subjects: 50
Study 17804330 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon and Pulp Canal Sealer
Number of subjects: 50
Study 17804330 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoRez methacrylate‐based endodontic sealer
Number of subjects: 50
Study 17804330 — intervention group
Group type: EXPERIMENTAL
Intervention: Not obturated
Number of subjects: 50
Study 17804330 — intervention group
Group type: COMPARATOR
Intervention: Gutta‐percha pellets
Number of subjects: 50
Study 17804330 — intervention group
Group type: COMPARATOR
Intervention: Resilon pellets
Number of subjects: 50
Study 15982798 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomally encapsulated recombinant human Superoxide Dismutase (lrhSOD)
Number of subjects: 39
Study 15982798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 12077091 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bb‐12 supplementation (bifidobacteria treated group)
Number of subjects: 21
Study 12077091 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (EHF without supplementation)
Number of subjects: 21
Study 10207969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital nerve block with 0.125% bupivacaine
Number of subjects: 30
Study 10207969 — intervention group
Group type: COMPARATOR
Intervention: Peri-incisional infiltration with 0.125% bupivacaine
Number of subjects: 30
Study 7715290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid
Number of subjects: 1493
Study 1916869 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hour infusion of amphotericin B
Number of subjects: 33
Study 1916869 — intervention group
Group type: COMPARATOR
Intervention: Four-hour infusion of amphotericin B
Number of subjects: 33
Study 7044099 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (cyclophosphamide, methotrexate, and 5‐fluorouracil)
Number of subjects: 34
Study 7044099 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 34
Study 7044099 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy
Number of subjects: 34
Study 31898389 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 0
Study 31898389 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 0
Study 30865794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month regimen of daily rifapentine plus isoniazid
Number of subjects: 3000
Study 30865794 — intervention group
Group type: COMPARATOR
Intervention: 9-month regimen of isoniazid alone
Number of subjects: 3000
Study 29629009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position with legs on the stool (LS group)
Number of subjects: 100
Study 29629009 — intervention group
Group type: COMPARATOR
Intervention: Sitting position with legs remaining on the operating table (LT group)
Number of subjects: 100
Study 29629009 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 26063218 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses with added support under the first metatarso-phalangeal joint
Number of subjects: 20
Study 25099962 — intervention group
Group type: EXPERIMENTAL
Intervention: K90 (isometric training at long muscle lengths for 8 weeks)
Number of subjects: 28
Study 25099962 — intervention group
Group type: EXPERIMENTAL
Intervention: K50 (isometric training at short muscle lengths for 8 weeks)
Number of subjects: 28
Study 25099962 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 22042247 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-μg SS (scarification of the skin)
Number of subjects: 24
Study 22042247 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-μg SS (scarification of the skin)
Number of subjects: 24
Study 22042247 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-μg ID (intradermal)
Number of subjects: 24
Study 22042247 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-μg ID (intradermal)
Number of subjects: 24
Study 19158556 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond burr superficial keratectomy (DBSK)
Number of subjects: 48
Study 19158556 — intervention group
Group type: COMPARATOR
Intervention: Epithelial debridement (ED)
Number of subjects: 48
Study 17238129 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind long-term efficacy (DBLE) design
Number of subjects: 0
Study 17238129 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized withdrawal (RW) design
Number of subjects: 0
Study 15190088 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation during walking
Number of subjects: 2
Study 15190088 — intervention group
Group type: COMPARATOR
Intervention: Cerebellar subjects
Number of subjects: 2
Study 15190088 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2
Study 12002243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring relationships lasting a year or longer
Number of subjects: 1138
Study 12002243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring relationships that terminated within a very short period of time
Number of subjects: 1138
Study 12002243 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adolescents
Number of subjects: 1138
Study 12002243 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents referred for services or with sustained emotional, sexual or physical abuse
Number of subjects: 1138
Study 12002243 — intervention group
Group type: EXPERIMENTAL
Intervention: Married volunteers aged 26‐30 and those with lower incomes
Number of subjects: 1138
Study 12002243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic factors (race, gender, relationship quality)
Number of subjects: 1138
Study 9811072 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher inspired oxygen (0.25 L/min higher than baseline, SaO2 >97%)
Number of subjects: 16
Study 9811072 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy preterm infants)
Number of subjects: 16
Study 7545214 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5, 1, or 1.5 micrograms/kg of rhG‐CSF daily for 4 weeks, followed by 4 weeks resting, then rhG‐CSF plus 6 MU of rIFN 3 times weekly for 4 weeks, followed by 6 MU of rIFN alone for 4 weeks, then 3 MU of rIFN for 16 weeks
Number of subjects: 15
Study 2523644 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 to 5 mg twice daily, or 2.5 to 10 mg once daily)
Number of subjects: 118
Study 2523644 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (once-daily)
Number of subjects: 118
Study 2523644 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (twice-daily)
Number of subjects: 118
Study 2523644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 506802 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 37
Study 506802 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg once daily
Number of subjects: 37
Study 506802 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg and 200 mg)
Number of subjects: 37
Study 506802 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 37
Study 31801173 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record (EHR) intervention
Number of subjects: 150
Study 28724418 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 180
Study 28724418 — intervention group
Group type: COMPARATOR
Intervention: No-CTO PCI
Number of subjects: 180
Study 28724418 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI in dysfunctional but viable segments (TEI < 50%)
Number of subjects: 180
Study 28724418 — intervention group
Group type: COMPARATOR
Intervention: No-CTO PCI in dysfunctional but viable segments (TEI < 50%)
Number of subjects: 180
Study 28724418 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI with Rentrop grade 2-3 collaterals
Number of subjects: 180
Study 28724418 — intervention group
Group type: COMPARATOR
Intervention: CTO PCI with Rentrop grade 0-1 collaterals
Number of subjects: 180
Study 24863143 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGASUS psychoeducational program
Number of subjects: 108
Study 24225069 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive pacing therapy
Number of subjects: 0
Study 24225069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 0
Study 24225069 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise therapy
Number of subjects: 0
Study 24225069 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist medical care
Number of subjects: 0
Study 21457979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 79